{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:24:27Z","timestamp":1793129067196,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2023JJ30847"],"award-info":[{"award-number":["2023JJ30847"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00210-024-03135-2","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T01:01:38Z","timestamp":1715734898000},"page":"7905-7912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Clinical features, treatment, and outcome of pembrolizumab induced cholangitis"],"prefix":"10.1007","volume":"397","author":[{"given":"Weilun","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"issue":"1","key":"3135_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/liv.15340","volume":"43","author":"P Berry","year":"2023","unstructured":"Berry P, Kotha S, Zen Y, Papa S, El Menabawey T, Webster G et al (2023) Immune checkpoint inhibitor-related cholangiopathy: Novel clinicopathological description of a multi-centre cohort. Liver Int 43(1):147\u2013154. https:\/\/doi.org\/10.1111\/liv.15340","journal-title":"Liver Int"},{"issue":"4","key":"3135_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.18.00005","volume":"14","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Thompson JA (2018) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract 14(4):247\u2013249. https:\/\/doi.org\/10.1200\/JOP.18.00005","journal-title":"J Oncol Pract"},{"issue":"10212","key":"3135_CR3","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, Jr, et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915\u20131928. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7","journal-title":"Lancet"},{"issue":"4","key":"3135_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559\u2013574. https:\/\/doi.org\/10.1093\/annonc\/mdv623","journal-title":"Ann Oncol"},{"issue":"14","key":"3135_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P et al (2019) Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 134(14):1144\u20131153. https:\/\/doi.org\/10.1182\/blood.2019000324","journal-title":"Blood"},{"issue":"4","key":"3135_CR6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/flgastro-2018-101146","volume":"10","author":"V Cheung","year":"2019","unstructured":"Cheung V, Gupta T, Payne M, Middleton MR, Collier JD, Simmons A et al (2019) Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterol 10(4):364\u2013371. https:\/\/doi.org\/10.1136\/flgastro-2018-101146","journal-title":"Frontline Gastroenterol"},{"issue":"1","key":"3135_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","volume":"7","author":"MA Couey","year":"2019","unstructured":"Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD et al (2019) Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 7(1):165. https:\/\/doi.org\/10.1186\/s40425-019-0645-6","journal-title":"J Immunother Cancer"},{"issue":"4","key":"3135_CR8","doi-asserted-by":"publisher","first-page":"e000268","DOI":"10.1136\/esmoopen-2017-000268","volume":"2","author":"GJ Doherty","year":"2017","unstructured":"Doherty GJ, Duckworth AM, Davies SE, Mells GF, Brais R, Harden SV et al (2017) Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open 2(4):e000268. https:\/\/doi.org\/10.1136\/esmoopen-2017-000268","journal-title":"ESMO Open"},{"issue":"3","key":"3135_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/annonc\/mdw649","volume":"28","author":"F Gelsomino","year":"2017","unstructured":"Gelsomino F, Vitale G, D\u2019Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28(3):671\u2013672. https:\/\/doi.org\/10.1093\/annonc\/mdw649","journal-title":"Ann Oncol"},{"issue":"1","key":"3135_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10637-017-0484-6","volume":"36","author":"F Gelsomino","year":"2018","unstructured":"Gelsomino F, Vitale G, Ardizzoni A (2018) A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Invest New Drugs 36(1):144\u2013146. https:\/\/doi.org\/10.1007\/s10637-017-0484-6","journal-title":"Invest New Drugs"},{"issue":"12","key":"3135_CR11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C et al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"issue":"2","key":"3135_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/jcp.2004.023507","volume":"59","author":"K Harada","year":"2006","unstructured":"Harada K, Isse K, Nakanuma Y (2006) Interferon gamma accelerates NF-kappaB activation of biliary epithelial cells induced by Toll-like receptor and ligand interaction. J Clin Pathol 59(2):184\u2013190. https:\/\/doi.org\/10.1136\/jcp.2004.023507","journal-title":"J Clin Pathol"},{"issue":"2","key":"3135_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12328-022-01593-w","volume":"15","author":"H Hori","year":"2022","unstructured":"Hori H, Fujita K, Nishio A, Nishijima M, Inaba M, Anami T, Matsui S, Kitamura Y, Matsuoka R, Watanabe A (2022) Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature. Clin J Gastroenterol 15(2):475\u2013479. https:\/\/doi.org\/10.1007\/s12328-022-01593-w","journal-title":"Clin J Gastroenterol"},{"issue":"11","key":"3135_CR14","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL (2016) Pembrolizumab (Keytruda). Hum Vaccin Immunother 12(11):2777\u20132789. https:\/\/doi.org\/10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"3135_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000530009","volume":"16","author":"I Liang","year":"2023","unstructured":"Liang I, Chu G, Zielinski R (2023) Pembrolizumab Induced sclerosing cholangitis: why you need a liver biopsy. Case Rep Oncol 16(1):182\u2013187. https:\/\/doi.org\/10.1159\/000530009","journal-title":"Case Rep Oncol"},{"issue":"23","key":"3135_CR16","doi-asserted-by":"publisher","first-page":"01037","DOI":"10.1016\/j.cgh.2023.12.008","volume":"S1542-3565","author":"L Meunier","year":"2023","unstructured":"Meunier L, Hountondji L, Jantzem H, Faillie JL, Maria A, Palassin P, MonRIO Group (2023) Cholangitis induced by immune checkpoint inhibitors: analysis of pharmacovigilance data. Clin Gastroenterol Hepatol. S1542-3565(23):01037\u20136. https:\/\/doi.org\/10.1016\/j.cgh.2023.12.008","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"6","key":"3135_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","volume":"55","author":"K Mizuno","year":"2020","unstructured":"Mizuno K, Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T et al (2020) Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol 55(6):653\u2013661. https:\/\/doi.org\/10.1007\/s00535-020-01677-9","journal-title":"J Gastroenterol"},{"issue":"2","key":"3135_CR18","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.30189","volume":"69","author":"K Ogawa","year":"2019","unstructured":"Ogawa K, Kamimura K, Terai S (2019) Antiprogrammed cell death-1 immunotherapy-related secondary sclerosing cholangitis. Hepatology 69(2):914\u2013916. https:\/\/doi.org\/10.1002\/hep.30189","journal-title":"Hepatology"},{"issue":"19","key":"3135_CR19","doi-asserted-by":"publisher","first-page":"e59125","DOI":"10.1172\/jci.insight.59125","volume":"3","author":"A Osa","year":"2018","unstructured":"Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T et al (2018) Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3(19):e59125. https:\/\/doi.org\/10.1172\/jci.insight.59125","journal-title":"JCI Insight"},{"issue":"3","key":"3135_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Par\u00e9s","year":"2006","unstructured":"Par\u00e9s A, Caballer\u00eda L, Rod\u00e9s J (2006) Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 130(3):715\u2013720. https:\/\/doi.org\/10.1053\/j.gastro.2005.12.029","journal-title":"Gastroenterology"},{"issue":"1S Suppl 1","key":"3135_CR21","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","volume":"33","author":"B Pi","year":"2021","unstructured":"Pi B, Wang J, Tong Y, Yang Q, Lv F, Yu Y (2021) Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. Eur J Gastroenterol Hepatol 33(1S Suppl 1):e858\u2013e867. https:\/\/doi.org\/10.1097\/MEG.0000000000002280","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"3135_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cld.2007.11.007","volume":"12","author":"NS Reau","year":"2008","unstructured":"Reau NS, Jensen DM (2008) Vanishing bile duct syndrome. Clin Liver Dis. 12(1):203\u201317, x. https:\/\/doi.org\/10.1016\/j.cld.2007.11.007","journal-title":"Clin Liver Dis."},{"issue":"12","key":"3135_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1042\/CS20110184","volume":"121","author":"MG Roma","year":"2011","unstructured":"Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, S\u00e1nchez Pozzi EJ (2011) Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond) 121(12):523\u2013544. https:\/\/doi.org\/10.1042\/CS20110184","journal-title":"Clin Sci (Lond)"},{"issue":"9","key":"3135_CR24","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/jgh.15797","volume":"37","author":"N Suzuki","year":"2022","unstructured":"Suzuki N, Ikeda Y, Ono M, Ohmori G, Maeda M (2022) Gastrointestinal: Immune-related sclerosing cholangitis with pembrolizumab: Imaging and histological features. J Gastroenterol Hepatol 37(9):1652. https:\/\/doi.org\/10.1111\/jgh.15797","journal-title":"J Gastroenterol Hepatol"},{"issue":"28","key":"3135_CR25","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.3748\/wjg.v28.i28.3732","volume":"28","author":"T Tanaka","year":"2022","unstructured":"Tanaka T, Sakai A, Tsujimae M, Yamada Y, Kobayashi T et al (2022) Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report. World J Gastroenterol 28(28):3732\u20133738. https:\/\/doi.org\/10.3748\/wjg.v28.i28.3732","journal-title":"World J Gastroenterol"},{"key":"3135_CR26","doi-asserted-by":"publisher","unstructured":"Taylor C, Reno M, Sharma D (2021) Secondary sclerosing cholangitis: a lesser known side effect of pembrolizumab therapy. Am J Clin Pathol (Supplement_1):Supplement_1. https:\/\/doi.org\/10.1093\/ajcp\/aqab191.263","DOI":"10.1093\/ajcp\/aqab191.263"},{"key":"3135_CR27","doi-asserted-by":"publisher","first-page":"102328","DOI":"10.1016\/j.jaut.2019.102328","volume":"105","author":"B Terziroli Beretta-Piccoli","year":"2019","unstructured":"Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G et al (2019) The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun 105:102328. https:\/\/doi.org\/10.1016\/j.jaut.2019.102328","journal-title":"J Autoimmun"},{"issue":"3","key":"3135_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1055\/s-0043-124969","volume":"50","author":"JD Waye","year":"2018","unstructured":"Waye JD, Thomas-Gibson S (2018) How I do colonoscopy. Endoscopy 50(3):259\u2013262. https:\/\/doi.org\/10.1055\/s-0043-124969","journal-title":"Endoscopy"},{"issue":"12","key":"3135_CR29","doi-asserted-by":"publisher","first-page":"e232505","DOI":"10.1136\/bcr-2019-232505","volume":"12","author":"H Williams","year":"2019","unstructured":"Williams H, Aitchison R (2019) Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis. BMJ Case Rep 12(12):e232505. https:\/\/doi.org\/10.1136\/bcr-2019-232505","journal-title":"BMJ Case Rep"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03135-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03135-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03135-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T09:05:43Z","timestamp":1727946343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03135-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3135"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03135-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"1 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not require an ethical board approval because the study was a retrospective study and did not involve sensitive personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}